AstraZeneca, Russia's Sputnik V developer to sign cooperation memorandum

President Vladimir Putin hailed British drugmaker AstraZeneca's decision to test combining its own experimental Covid-19 vaccine with Russia's Sputnik V shot

AstraZeneca
Clinical trials, still under way, have shown Sputnik has an efficacy of over 90 per cent
Reuters
1 min read Last Updated : Dec 22 2020 | 2:28 AM IST
Britain’s AstraZeneca and Russia's Gamaleya Institute, which developed the Sputnik V vaccine, will sign a memorandum of intent on cooperation on Monday, the Kremlin said.
 
Russia’s RDIF sovereign wealth fund said this month AstraZeneca would start clinical trials to test a combination of its experimental Covid-19 vaccine with the Sputnik V shot to see if this can boost the efficacy of the British drugmaker's vaccine.
 
President Vladimir Putin hailed British drugmaker AstraZeneca's decision to test combining its own experimental Covid-19 vaccine with Russia's Sputnik V shot.
 

Also Read

Clinical trials, still under way, have shown Sputnik has an efficacy of over 90 per cent.

Frontline workers, 75 years+ should get vaccine next: CDC
 
An advisory panel on Sunday recommended US frontline essential workers and people 75 and older should be next in line to get inoculated as the distribution of Moderna’s vaccine, the second approved coronavirus vaccine, began across the country. The US CDC voted 13 to 1 to recommend 30 million frontline essential workers have the next priority for the vaccines.




One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :AstraZenecaRussiaCoronavirus Vaccine

Next Story